Esta web utiliza cookies. Si continúas navegando consideramos que aceptas su uso.
Más información
Aceptar
I Jornadas Científicas del IMIB-Arrixaca
Acceso Personal
Contacto
Aviso Legal
Inicio
Bienvenida
Comités
Ponencias
Comunicaciones
Programa
Fechas clave
Inscripciones
Selección comunicaciones
Enviar comunicación
Patrocinadores
Sede
Imprimir
AMNIOTIC MEMBRANE-DERIVED MESENCHYMAL STEM CELLS IMPROVE MYOCARDIAL FUNCTION AND SURVIVAL IN EXPERIMENTAL CARDIOMYOPATHY
Autores:
JESUS TALAVERA LOPEZ
, ALEJANDRO GIRALDO, Mª JOSEFA FERNANDEZ DEL PALACIO, CARLOS MICÓ VALLS,
ESTHER MARÍA GARCÍA NAVARRO
,
DAVID GARCÍA BERNAL
, GAVIN BROOKS,
NOEMI MARIN ATUCHA
,
JOSE MARIA MORALEDA JIMÉNEZ
,
Grupos de investigación:
[GI/IMIB/C061/2011] TRASPLANTE HEMATOPOYÉTICO / TERAPIA CELULAR
Comunicación:
Antecedentes:
Amniotic membrane-derived mesenchymal stem cell (AM-MSC) transplant evokes demonstrable benefits in models of ischaemic cardiomyopathy. We compared the effects on cardiac function of AM-MSC therapy via percutaneous intramyocardial injection (IMI) versus intravenous (IV) injection in a model of anthracycline-induced cardiomyopathy (AICM).
Métodos:
Cardiomyopathy was induced in New Zealand rabbits with IV infusions of daunorubicin (4 mg/kg, weekly for 6 weeks). At 8 weeks after the first dose of the anthracycline, one group received one dose of 5 million AM-MSCs via contrast echocardiography-guided percutaneous IMI (IMI Group, n=8). A second group received IV therapy with 5 million/kg AM-MSCs (IV Group, n=8), 24 hours after each weekly cycle of daunorubicin. A third group received no cell therapy (AICM Group, n=8). A final group neither received daunorubicin nor cell therapy, thus constituting an age-matched Control Group (n=8). A complete echocardiographic exam was performed at baseline and repeated every two weeks.
Resultados:
In all groups, ventricular systolic and diastolic function was normal at baseline but significantly altered by daunorubicin in IMI and AICM groups at 8 weeks, consistent with the development AICM (Figure). In contrast, the IV group did not exhibit significant alterations of myocardial function at 8 weeks. Whilst ventricular systolic function improved at 10 and 12 week time points in IMI group, it further deteriorated in AICM group. Moderate alterations in myocardial function were apparent in IV group at 10 and 12 week time points, but significantly less conspicuous than in AICM group. Survival in rabbits from IMI and IV groups was improved (77% and 75%, respectively) compared to AICM group (22%) (p < 0.04, Mantel-Cox test).
Conclusiones:
These results indicated that percutaneous IMI and IV therapy with AM-MSC improves/preserves the ventricular systolic function and survival in AICM
Instituto de Investigación Sanitaria Acreditado
Inicio
Grupo de Investigación
Miembros
Proyectos
Colaboraciones
Servicios
Recursos formativos
Producción Científica
Publicaciones
Tesis
Novedades
Noticias
Eventos
Convocatorias
Agenda